Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Ticker SymbolCDXS
Company nameCodexis Inc
IPO dateApr 22, 2010
CEODr. Stephen G. Dilly, Ph.D.
Number of employees188
Security typeOrdinary Share
Fiscal year-endApr 22
Address200 Penobscot Dr
CityREDWOOD CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94063
Phone16504218100
Websitehttps://www.codexis.com/
Ticker SymbolCDXS
IPO dateApr 22, 2010
CEODr. Stephen G. Dilly, Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data